FXR (NR1H4) binding and activity modulating compounds
The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
1. A compound according to the Formula (1),
wherein
R is selected from the group consisting of COOR 6 , CONR 7 R 8 , tetrazolyl, SO 2 NR 7 R 8 , C 1-6 alkyl, SO 2 —C 1-6 alkyl, and H; R 6 is H or C 1-6 alkyl; R 7 and R 8 are each independently selected from the group consisting of H, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkylene-R 9 , and SO 2 —C 1-6 alkyl; R 9 is selected from the group consisting of COOH, OH, and SO 3 H;
A is selected from the group consisting of phenyl, pyridyl, pyrimidyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, and oxadiazolyl, each optionally substituted with one or two groups each independently selected from the group consisting of OH, O—C 1-6 alkyl, O-halo-C 1-6 alkyl, C 1-6 alkyl, halo-C 1-6 alkyl, C 3-6 cycloalkyl, and halogen;
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, and pyrimidyl, each optionally substituted with one or two groups each independently selected from the group consisting of C 1-6 alkyl, halo-C 1-6 alkyl, halogen, and CF 3 ;
Y is N or CH;
Z is selected from the group consisting of
X is selected from the group consisting of CH, N, and NO;
R 1 is selected from the group consisting of hydrogen, C 1-3 alkyl, C 3-6 cycloalkyl, and C 4-5 alkylcycloalkyl, wherein C 1-3 alkyl is optionally substituted with 1 to 3 substituents each independently selected from the group consisting of halogen, hydroxy, and C 1-6 alkoxy; and
R 2 and R 3 are each independently selected from the group consisting of hydrogen, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, and halogen;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein R-A is of a formula selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , wherein Q is
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 , wherein Z is
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 , selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one excipient.
7. A compound according to the Formula (2)
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and at least one excipient.
9. A compound according to the Formula (3)
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising the compound of claim 9 , or a pharmaceutically acceptable salt thereof, and at least one excipient.